Several dysregulated kinases in the PI3K/AKT/mTOR signaling pathway have been involved in multiple hallmarks of cancer such as cell proliferation and metastatic processes in multiple solid and hematologic malignancies and FDA-approved PI3K inhibitors targeting them e.g., copanlisib, idelalisib, duvelisib, umbralisib for hematologic malignancies and alpelisib for PIK3CA mutated advanced breast cancer43. This evidence concerns the gene PIK3CA and hematologic disorder.